There’s nothing real about the U.S. recovery. Markets may have rallied well off January 2016 lows, but there’s a great deal of underlying weakness. “This economy would have to improve dramatically to get to mediocre,” noted Peter Schiff early Monday morning. “The Fed can’t raise rates because they don’t’ want to poke too many holes…
DetailsThe first quarter of 2016 came in a whimper and ended with a bang… In the first week of the year, the Dow Jones fell 2,200 points, wiping out trillions of shareholder value. Investors had many concerns — the China slowdown, falling oil and commodity prices, and the Federal Reserve’s actions. Fears of a global…
DetailsWhen all else fails, try sex. It’s one of the oldest and irrefutable laws of advertising… Sex sells. GoDaddy (GDDY) used sex to parlay its web domain registration business into a $5 billion empire. There are hundreds of companies which can register the domain address for you. Hover, Namecheap, Gandi, Name.com, Google and more provide…
DetailsIt would be laughable it if it wasn’t going to be so painful for so many. As you surely know by now, California and New York have passed (or are about to pass) $15/hr minimum wage laws. At first glance, it’s an economic death sentence for millions of workers in their respective states. The politicians…
DetailsAfter more than $605 billion worth of mergers and acquisitions (M&A), 2015 became the hottest on record for the biotech and pharmaceutical industry. Even though the first quarter of 2016 showed slower M&A activity, I can assure you the trend is far from over. Just last year, AbbVie (ABBV) paid $21 billion for Pharmacyclics, a…
DetailsBiotech may have had a rough start to the year, lagging many other sectors. But don’t count it out just yet. In fact, buy all you can. The same strong catalysts and fundamentals are still firmly in place. There are 80 million baby boomers that just started retiring. We have millions of newly insured American,…
DetailsBack in 2008 a friend of mine handed me a book and said, “This is going to blow your mind.” I read it (a bit of unsolicited life advice: always read a book someone gives you, go to a restaurant someone recommends to you, etc.). It was a good read. Entertaining. Mind wasn’t blown though.…
DetailsAfter plunging from a high of $300 in 2008, the Guggenheim Solar ETF (TAN) now sits around $22.35 a share. Even after a tax credit-fueled rally, and the 2015 Climate Change conference that thrust solar related stocks back into the spotlight, growth, debt, high-flier bankruptcies, and widespread industry losses remind us of the dangers involved…
DetailsThe opportunity in Brazil is playing out just as we expected. Maybe a little faster. Earlier this week we wrote: The combination of events — worldwide stock rebound, commodities bouncing back, and the very real potential of a new government — have brought a renewed hope to Brazil. Since then events have played out right…
DetailsIt’s the news we’ve waited years to see… And it’s quite a game changer for hundreds of thousands. Just last night, an FDA advisory panel committee awarded the company full critical endorsement of ACADIA Pharmaceuticals (ACAD) Parkinson’s disease Psychosis (PDP) drug… The panel had to vote on whether the drug was effective, safe and if…
DetailsYou’ve been hearing it for years… BusinessInsider (2011): One Of The Best Economic Forecasters Calls For A “New Recession” In The US Forbes (2012): The Coming Obama Recession of 2013 Yahoo Finance in (2014): Never Mind the Recovery, Get Ready for the Next Recession Each year there’s a call for a new recession. Each year…
DetailsIt’s been one of the most powerful, most lucrative moves of the last five years… And it’s far from over… Despite recent headwinds, political bashing, and fears of a popped bubble, biotech has still significantly outperformed the broader markets. In fact, over the last five years – as measured by the iShares NASDAQ Biotech Index…
Details